Connect with us

Healthcare Buzz

Glenmark’s Consolidated Revenue Rises 15.95 Percent In Q3 FY 2018-19

Glenmark Pharmaceuticals Limited has reported its financial results for the third quarter ended December 31 of the financial year 2018-19. In the third quarter ended December 31, 2018, Glenmark’s consolidated revenue was at Rs 25,550.45 million (USD 355.87 million) as against Rs 22,036.62 million (USD 340.69 million) in the previous corresponding quarter, recording an increase of 15.95 percent. Consolidated net profit was at Rs 1163.41 million for the quarter ended December 31, 2018 as compared to Rs 1047.43 million in the previous corresponding quarter, registering an increase of 11.07 percent. Consolidated EBITDA was at Rs 4346.80 million in the quarter ended December 31, 2018 as against Rs 3226.93 million in the previous corresponding quarter, an increase of 34.70 percent.

Glenn Saldanha
Chairman and Managing Director
Glenmark Pharmaceuticals

“We have reported healthy numbers in Q3 on the back of good growth in our key markets like the US, India, and Europe.”

Copyright © 2024 Medical Buyer

error: Content is protected !!